US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

520.65

+2.820.54%

Number of Gainers:3

Number of Losers:1

Number of Flat:- -

PE:- -

High:532.35

Open:518.57

Low:508.03

Close:517.84

Loading ...

BRIEF-Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation

Illumina and Tempus Partner to Drive the Future of Precision Medicine Through Genomic AI Innovation

THOMSON REUTERS

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?

Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today

Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?

Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)

Recursion Pharmaceuticals call volume above normal and directionally bullish

Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing

THOMSON REUTERS

Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%

THOMSON REUTERS

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.

CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know

Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Thermo Fisher (TMO) Surges 8.2%: Is This an Indication of Further Gains?

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Why Tempus AI Inc. (TEM) Went Down On Tuesday?

Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":520.65436,"timestamp":1744747199999,"preClose":517.838,"halted":0,"volume":28782440,"delay":0,"changeRate":0.005439,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":2.816345,"latestTime":"04-15 16:00:00 EDT","open":518.57245,"high":532.3509,"low":508.03076,"amount":453038322.149727,"amplitude":0.046965,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744810200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.902817,"peRate":-7.666492,"turnoverRate":0.047354,"increases":3,"decrements":1,"flats":0,"marketCap":14715202944,"floatMarketCap":10685945088},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":532.3509,"amplitude":0.046965,"preClose":517.838,"low":508.03076,"pbRate":"3.902817","latestPrice":520.65436,"volume":28782440,"delay":0,"open":518.57245,"prevYearClose":530.4984,"prevWeekClose":514.1271,"prevMonthClose":527.803,"prevQuarterClose":527.803,"fiveDayClose":423.3526,"twentyDayClose":573.8071,"sixtyDayClose":531.3271,"secType":"PLATE","market":"US","turnoverRate":0.047354,"peRate":-7.666492,"marketCap":14715202944,"floatMarketCap":10685945088,"timestamp":1744747199999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":3,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527482412","title":"BRIEF-Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527482412","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527482412?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:36","pubTimestamp":1744724185,"startTime":"0","endTime":"0","summary":"BRIEF-Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai InnovationApril 15 (Reuters) - Illumina Inc ILMN.O:ILLUMINA AND TEMPUS PARTNER TO DRIVE THE FUTURE OF PRE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA6XWGHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4613","LU1861558580.USD","ILMN","TEM","BK4534","BK4121","BK4535","BK4611","LU1861559042.SGD","BK4548","BK4585"],"gpt_icon":0},{"id":"2527411228","title":"Illumina and Tempus Partner to Drive the Future of Precision Medicine Through Genomic AI Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527411228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527411228?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:15","pubTimestamp":1744722904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA6XWGHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4611","BK4535","ILMN","BK4588","BK4613","LU1861558580.USD","TEM","BK4585","BK4534","LU1861559042.SGD","BK4548"],"gpt_icon":0},{"id":"2527414694","title":"Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527414694","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527414694?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:15","pubTimestamp":1744722900,"startTime":"0","endTime":"0","summary":"Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease. SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ --Illumina Inc.  and Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are:  challenges inherent in developing and launching new products and services, includi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/illumina-tempus-partner-drive-future-131500785.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/illumina-tempus-partner-drive-future-131500785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4613","LU1861558580.USD","ILMN","TEM","BK4534","BK4121","BK4535","BK4611","LU1861559042.SGD","BK4548","BK4585"],"gpt_icon":1},{"id":"2527943012","title":"Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527943012","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527943012?lang=en_us&edition=fundamental","pubTime":"2025-04-15 13:07","pubTimestamp":1744693671,"startTime":"0","endTime":"0","summary":"Wall Street’s main indices kicked off the trading week in the green territory, albeit with minimal gains, as investors stayed on the sidelines while continuing to digest President Donald Trump’s temporary tax reprieve on technology companies.The S&P 500 recorded the highest gain, up 0.79 percent, while the Dow Jones came second at 0.78 percent. The tech-heavy Nasdaq was also up by 0.64 percent.Meanwhile, 10 companies, predominantly in the technology sector, bucked a broader market optimism, booking modest declines during the session. In this article, let us explore Monday’s 10 worst performers and the reasons behind their gains.A pharmacist in a hospital pharmacy stands next to a row of various drug containers.According to the FDA, the initiative was designed to replace animal testing with “more effective human-relevant methods” in the development of monoclonal antibody therapies and other drugs.According to the FDA, it will begin to encourage the inclusion of New Approach Methodologie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-recursion-pharmaceuticals-inc-rxrx-050751253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4609","BK4539","BK4611","RXRX","BK4139"],"gpt_icon":1},{"id":"2527117371","title":"Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527117371","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527117371?lang=en_us&edition=fundamental","pubTime":"2025-04-15 08:05","pubTimestamp":1744675508,"startTime":"0","endTime":"0","summary":"20:03 EDT Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-460k-shares-of-recursion-pharmaceuticals-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-460k-shares-of-recursion-pharmaceuticals-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","RXRX","BK4588","ARKK","BK4544","BK4585","BK4139","BK4609","BK4548","BK4539"],"gpt_icon":0},{"id":"2527140714","title":"Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”","url":"https://stock-news.laohu8.com/highlight/detail?id=2527140714","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527140714?lang=en_us&edition=fundamental","pubTime":"2025-04-15 03:35","pubTimestamp":1744659310,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.  stands against other stocks that Jim Cramer discusses.In his latest appearance on CNBC’sSquawk on the Street, Jim Cramer suggested the recent tariffs might not simply be about economic leverage. He hinted at a deeper agenda within parts of the administration that goes beyond trade policy:. “There’s plenty of sense that something’s going to happen that’s going to take this away. In fact, just because of what we saw the other day with it going to 10 percent, I don’t see that at all. I think these are very different kinds of tariffs. I mean, this is a tariff where I think there’s some people with the administration who actually ultimately have a goal of regime change.“READ ALSO:Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key StocksandJim Cramer Questions Market Logic and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-recursion-rxrx-ai-193510944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4611","NQmain","QID","PSQ",".IXIC","BK4609","SQQQ","RXRX","TQQQ","MNQmain","USAW.SI","BK4539","QLD","TSYW.SI","USJW.SI","BK4548","BK4139","NVIW.SI"],"gpt_icon":1},{"id":"2527199861","title":"Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527199861","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527199861?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:09","pubTimestamp":1744636140,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  shares soared 27.7% in the last trading session to close at $5.76. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.1% loss over the past four weeks.Earlier this month, the company announced that it has dosed the first patient in its early-stage study of investigational candidate, REC-3565, for treating relapsed or refractory (R/R) B-cell lymphomas. REC-3565 is a selective MALT1 inhibitor developed using Recursion Pharmaceuticals’ proprietary AI-driven Recursion OS platform. The growing optimism related to this development might have driven the recent share price rally.For Recursion Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RXRX going forward to see if this recent jump can","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-recursion-pharmaceuticals-rxrx-130900685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4609","BK4539","BK4611","BK4548","AQST","BK4007","RXRX","BK4139"],"gpt_icon":1},{"id":"2527995994","title":"Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527995994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527995994?lang=en_us&edition=fundamental","pubTime":"2025-04-13 22:50","pubTimestamp":1744555838,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research Report)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-bruker-brkr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-bruker-brkr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1815336091.USD","BRKR","RXRX","BK4609","BK4139","BK4137","BK4548","HCSG","LU0757428866.USD","BK4539","BK4121","BK4611"],"gpt_icon":0},{"id":"2526902066","title":"Recursion Pharmaceuticals call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2526902066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526902066?lang=en_us&edition=fundamental","pubTime":"2025-04-12 00:05","pubTimestamp":1744387514,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 9,589 calls trading, 1.6x expected, and implied vol increasing over 27 points...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-22?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-22?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","RXRX","BK4609","BK4139","BK4548","BK4539"],"gpt_icon":0},{"id":"2526698309","title":"Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698309?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:32","pubTimestamp":1744378357,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4167","BK4121","BK4588","CERT","BK4611","BK4539","RXRX","ABSI","BK4548","BK4609","BK4585","SDGR"],"gpt_icon":0},{"id":"2526318698","title":"Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526318698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526318698?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:32","pubTimestamp":1744378357,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP02E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4121","BK4548","ABSI","BK4588","CERT","SDGR","BK4167","BK4609","BK4611","BK4539","RXRX","BK4139"],"gpt_icon":0},{"id":"2526664088","title":"Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2526664088","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526664088?lang=en_us&edition=fundamental","pubTime":"2025-04-11 19:37","pubTimestamp":1744371466,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, Beam Therapeutics' stock price might be vulnerable to their trading decisions. A total of 7 investors have a majority stake in the company with 51% ownership. Ownership research along with  analyst forecasts data  help provide a good understanding of opportunities in a stock. Every investor in Beam Therapeutics Inc.  should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 80% ownership. Put another way, the group faces the maximum upside potential .Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Our data indicates that hedge funds own 8.5% of Beam Therapeutics. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation  in the short term or medium term. Our data shows that FMR LLC is the largest s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-inc-nasdaq-beam-113746956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","QLD","BK4112","USAW.SI","BEAM","IE00BGHQF748.EUR","PSQ","BK4585","IE00BKPKM429.USD","USJW.SI","TSYW.SI","BK4535","BK4611","BK4556","BK4505","BK4588","NQmain",".IXIC","BK4139","LU2210149790.SGD","NDAQ","MNQmain","IE00B64PRP62.GBP","TQQQ","NVIW.SI","SQQQ","IE00B3QW5Z07.USD","QID","LU2210150020.SGD"],"gpt_icon":1},{"id":"2526525917","title":"CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526525917","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526525917?lang=en_us&edition=fundamental","pubTime":"2025-04-11 05:50","pubTimestamp":1744321811,"startTime":"0","endTime":"0","summary":"In the latest trading session, CRISPR Therapeutics AG  closed at $34.26, marking a -1.81% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.46%. Elsewhere, the Dow lost 2.5%, while the tech-heavy Nasdaq lost 4.31%.The the stock of company has fallen by 19.78% in the past month, lagging the Medical sector's loss of 10.85% and the S&P 500's loss of 5.27%.Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.26, up 11.89% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.24 million, up 947.2% from the year-ago period.Investors should also note any recent changes to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-stock-215011874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AG","BK4611","BK4210","LU1861558580.USD","LU1861559042.SGD","CRSP","BK4588","BK4556","BK4585","BK4139"],"gpt_icon":0},{"id":"2526451593","title":"Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2526451593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526451593?lang=en_us&edition=fundamental","pubTime":"2025-04-11 00:23","pubTimestamp":1744302180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 12:23 ET (16:23 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a9b4e43bbb37604adaeb10a55d437a8b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","BK4504","LU0158827781.USD","BK4539","BK4588","IE00BKVL7J92.USD","LU0225283273.USD","BK4534","LU1668664300.SGD","RXRX","LU0106831901.USD","LU2357305700.SGD","BK4139","LU1989772840.SGD","LU0314104364.USD","BK4548","LU1548497426.USD","BK4581","LU1363072403.SGD","LU2028103732.USD","LU0158827948.USD","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU0971096721.USD","LU2347655156.SGD","BK4585","LU1720051017.SGD","LU2271345857.HKD","BK4127","BK4516","LU0795875086.SGD","LU0795875169.SGD","LU0098860793.USD","LU2023251221.USD","LU1162221912.USD","LU2133065610.SGD","LU1074936037.SGD","BK4611","BK4609","LU0320765646.SGD","LU2089283258.USD","LU0267386448.USD","LU2111349929.HKD","LU1732800096.USD","LU1989772923.USD","LU2089284900.SGD","LU0912757837.SGD","LU0006306889.USD","LU0106261372.USD"],"gpt_icon":0},{"id":"2526518905","title":"Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526518905","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526518905?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:49","pubTimestamp":1744292940,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc.  shares ended the last trading session 12.6% higher at $16.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 45% loss over the past four weeks.The stock surged in response to the broader market rally after President Trump announced a 90-day pause on the sweeping tariffs against non-retaliating countries.This company is expected to post quarterly loss of $1.11 per share in its upcoming report, which represents a year-over-year change of +8.3%. Revenues are expected to be $15.34 million, up 107% from the year-ago quarter.For Beam Therapeutics, the consensus EPS estimate for the quarter has been revised 4.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on BEAM going forward to see if this recent jump can turn into more strength down the road.Th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-beam-moves-12-134900338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4611","BK4535","MGTX","BK4588","BK4585","BK4556","BK4505","BK4139","BEAM"],"gpt_icon":0},{"id":"2526552248","title":"Thermo Fisher (TMO) Surges 8.2%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526552248","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526552248?lang=en_us&edition=fundamental","pubTime":"2025-04-10 17:15","pubTimestamp":1744276500,"startTime":"0","endTime":"0","summary":"Thermo Fisher Scientific TMO shares ended the last trading session 8.2% higher at $453.55. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.5% loss over the past four weeks.Thermo Fisher scored a strong price increase, on investors’ optimism surrounding its impending 2025 first-quarter financial results, which is slated to release on April 23 before the opening bell. In the last reported quarter, the company achieved robust revenue growth across all product categories. Additionally, market is also upbeat about the company’s launch of latest customer-centric innovation, the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope .This maker of scientific instrument and laboratory supplies is expected to post quarterly earnings of $5.11 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $10.25 billion, down 0.9% from the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/thermo-fisher-tmo-surges-8-091500360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARAY","BK4082","LU1854103824.USD","LU2211815571.USD","LU2264538146.SGD","LU1023059063.AUD","LU2063271972.USD","LU2125910336.SGD","LU1153585028.USD","LU0096362180.USD","LU1064131342.USD","LU2125909247.SGD","LU2125909916.SGD","LU1791710400.SGD","IE00B2B36J28.USD","LU1815333072.USD","LU2089984988.USD","LU1291159041.SGD","LU1861558580.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00B19Z8W00.USD","IE00BKPKM429.USD","LU2357305700.SGD","LU2764262908.HKD","TMO","LU0011850046.USD","IE00BJT1NW94.SGD","LU0882574055.USD","LU2468319806.SGD","LU1854104046.USD","LU0061474960.USD","LU1548497426.USD","LU2041044095.USD","GB00BDT5M118.USD","LU2125909593.SGD","LU0640476718.USD","LU2764263039.SGD","BK4588","LU0342679015.USD","LU1720051108.HKD","LU2298321311.HKD","IE00BJJMRZ35.SGD","LU1983299246.USD","BK4611","LU2092937221.SGD","BK4585","BK4613","LU1989771016.USD"],"gpt_icon":1},{"id":"2526937643","title":"CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526937643","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526937643?lang=en_us&edition=fundamental","pubTime":"2025-04-09 21:00","pubTimestamp":1744203608,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics AG  has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this company have returned -26.2%, compared to the Zacks S&P 500 composite's -13.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 17.7%. The key question now is: What could be the stock's future direction?Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-attracting-130008048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4210","BK4585","LU1861558580.USD","BK4611","BK4139","AG","CRSP","LU1861559042.SGD","BK4556","BK4588"],"gpt_icon":1},{"id":"2526559363","title":"Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries","url":"https://stock-news.laohu8.com/highlight/detail?id=2526559363","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526559363?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:00","pubTimestamp":1744200000,"startTime":"0","endTime":"0","summary":"Kyiv, Ukraine and Salt Lake City, UT, April  09, 2025  (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058339/0/en/Recursion-and-Enamine-Release-New-AI-Enabled-Targeted-Compound-Libraries.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","RXRX","BK4609","BK4611","BK4539","BK4139"],"gpt_icon":1},{"id":"2526356270","title":"Why Tempus AI Inc. (TEM) Went Down On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526356270","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526356270?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:15","pubTimestamp":1744193710,"startTime":"0","endTime":"0","summary":"Wall Street’s main indices suffered a bloodbath on Tuesday, recording steep losses amid the looming deadline for President Donald Trump’s new round of tariffs for China that would see the latter slapped with a cumulative 104-percent import tax.The tech-heavy Nasdaq registered the heaviest fall, down by 2.15 percent, followed by the S&P 500’s 1.57 percent decline, and the Dow Jones’ 0.84-percent drop.Ten companies mirrored the broader decline, recording hefty losses during the day. In this article, we listed the 10 worst-performing names and detailed the reasons behind their drop.To come up with the list, we considered only the stocks with $2 billion market capitalization and $5 million in trading volume.Tempus AI saw its share prices drop by 12.81 percent on Tuesday to end at $37.23 apiece amid the overall market pessimism and the lack of fresh catalysts to boost buying appetite.The company appeared to be waiting on the sidelines for more updates from the ongoing Annual Needham Virtual","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-tempus-ai-inc-tem-101510939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861558580.USD","TEM","BK4613","BK4121","LU1861559042.SGD","BK4611"],"gpt_icon":1},{"id":"2525922298","title":"Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2525922298","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525922298?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:59","pubTimestamp":1744117160,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  said Tuesday the first patient has been dosed in a phase 1 clinical study of REC-3565 for the potential treatment of relapsed or refractory B-cell lymphomas.The investigational drug has demonstrated evidence of durable tumor regression in preclinical trials as a monotherapy and in combination with a BTK inhibitor, the company said.The two-part study will also evaluate REC-3565 as a monotherapy to identify a recommended dose for combination regimens, Recursion Pharmaceuticals added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4609","RXRX","BK4548","BK4139","BK4611","BK4539"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}